Compare Cinqair vs. Theophylline

Head-to-head comparisons of medication uses, side effects, ratings, and more.

Treats severe asthma.

Cinqair (reslizumab) works well to prevent severe asthma attacks and improves your breathing when other asthma medicines haven't worked for you, but it may be expensive.

No information currently available
  • You'll need to go in for your Cinqair (reslizumab) infusion only once every 4 weeks.
  • Cinqair (reslizumab) can reduce the frequency of asthma attacks and significantly raise lung capacity making it easier to breathe.
  • Unlike other similar medicines, Cinqair (reslizumab) doesn't increase your risk of urinary tract infections or cause headaches.
No information currently available
  • You'll need to be okay getting an infusion that takes up to 50 minutes to get the full dose.
  • Cinqair (reslizumab) can make you more vulnerable to getting certain types of infections.
  • Unlike other alternatives for asthma, this drug can sometimes cause a severe life-threatening allergic reaction.
No information currently available
Used for
  • Asthma Chronic obstructive pulmonary disease Exercise-induced asthma; Prophylaxis Nocturnal asthma
  • Apnea in the newborn; Adjunct Nocturnal asthma
Dosage forms
  • Injection
  • Pill
  • Extended release
  • Liquid
No pricing information available
Want to save even more money?
Sign up now for a 30-day trial and save up to 95% at CVS, Kroger, Albertsons, and other pharmacies.
Learn more
Not enough review data.Leave a review
Not enough review data.Leave a review
Side effects
The Cinqair (reslizumab) FDA package insert doesn’t have numbers about how common side effects are.
The Theo-24 (Theophylline) FDA package insert doesn’t have numbers about how common side effects are.
Risks and risk factors
  • Life-threatening allergic reaction
  • Sudden breathing problems (asthma attacks)
  • Abnormal tissue growth
  • Using corticosteroids
  • Parasitic infections
    • Helminth infections
  • Eosinophillic conditions
See more detailed risks and warnings
No information currently available